RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsDowngradesPrice Target
RBC Capital analyst Luca Issi downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Sector Perform and lowers the price target from $10 to $1.
RBC Capital analyst Luca Issi downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Sector Perform and lowers the price target from $10 to $1.